Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(167 produits)
- Bcr-Abl(118 produits)
- EGFR(581 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(180 produits)
- JAK(243 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(57 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2382 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
FLT3-ITD-IN-2
FLT3-ITD-IN-2 (Compound A1) is an inhibitor of the FLT3-ITD kinase, exhibiting an IC50 of 2.12 nM. It effectively suppresses the proliferation of the FLT3-dependent human AML cell line MOLM-13, with an IC50 of 25.65 nM. FLT3-ITD-IN-2 demonstrates antitumor activity against acute myeloid leukemia.Formule :C39H50N8O6Couleur et forme :SolidMasse moléculaire :726.86EGFR-IN-86
EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cellFormule :C20H21N7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :423.49VEGFR-2-IN-66
VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.Couleur et forme :Odour SolidhCA/VEGFR-2-IN-3
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2.Formule :C24H28N6O6SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.58SA-VA
SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.Formule :C50H53ClF3N11O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1044.54FW-1
FW-1 is a type I inhibitor of FLT3, with an IC50 of approximately 1 μM. It exhibits cytotoxic effects in FLT3-mutant AML cells, causes cell cycle arrest at the G0/G1 phase, and induces apoptosis in MV4-11 and MOLM-13 cells.
Formule :C24H27N7OCouleur et forme :SolidMasse moléculaire :429.517SJ1008030
CAS :SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.
Formule :C42H43N13O7SCouleur et forme :SolidMasse moléculaire :873.94FLT3 Ligand-Linker Conjugate 1
CAS :FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.Formule :C29H34N6O4S2Couleur et forme :SolidMasse moléculaire :594.748EGFR/BRAFV600E-IN-3
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.Formule :C25H18N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :422.44BRK inhibitor P21d hydrochloride
CAS :BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formule :C23H23ClFN7O2Couleur et forme :SolidMasse moléculaire :483.93EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Formule :C17H15N7O5SCouleur et forme :SolidMasse moléculaire :429.41FAK-IN-27
FAK-IN-27 (compound 8A) is a potent and selective inhibitor of FAK, with an IC50 of 4.968 nM. It effectively inhibits the proliferation of H1299 cells, with an IC50 of 0.28 μM, and is applicable for research in non-small cell lung cancer (NSCLC).Formule :C32H28ClN5O6Couleur et forme :SolidMasse moléculaire :613.17281EGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Formule :C22H16N4OSCouleur et forme :SolidMasse moléculaire :384.45LH168
LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.Formule :C29H31F3N6O2SCouleur et forme :SolidMasse moléculaire :584.66FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Formule :C28H26Cl2N4O3Couleur et forme :SolidMasse moléculaire :537.44JAK3-IN-14
CAS :JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.Formule :C18H13N3ODegré de pureté :98.29%Couleur et forme :SoildMasse moléculaire :287.32Ref: TM-T67754
1mg167,00€5mg409,00€10mg595,00€25mg888,00€50mg1.234,00€100mg1.665,00€1mL*10mM (DMSO)358,00€MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Formule :C25H29ClN8O2Couleur et forme :SolidMasse moléculaire :509HER2-IN-14
CAS :HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.Formule :C26H23ClF2N8O3Couleur et forme :SolidMasse moléculaire :568.96Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Degré de pureté :98%Couleur et forme :Odour SolidFGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].Formule :C26H27N4O6PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :522.49EGFR T790M/L858R-IN-9
EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.Formule :C26H27N7O3SCouleur et forme :SolidMasse moléculaire :517.603MET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Formule :C26H23N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :449.51TYVPANASL TFA
TYVPANASL TFA, a nine-amino-acid MHC I-binding CD8 T-cell epitope derived from HER2/neu, is utilized in the formulation of J-LEAPS vaccines [1].Couleur et forme :Odour SolidU3-1784
U3-1784 is a humanized monoclonal antibody targeting CD334, with anti-cancer activity, used in liver cancer research.Couleur et forme :LiquidMasse moléculaire :143.22 kDaAmuvatinib hydrochloride
CAS :Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Formule :C23H22ClN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :483.97SIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Formule :C44H50ClF2N9O5SCouleur et forme :SolidMasse moléculaire :890.44ALK-IN-29
ALK-IN-29 (compound 4c) exhibits inhibitory effects on tyrosine protein kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, displaying a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is applicable in cancer research.Formule :C29H32FN3OCouleur et forme :SolidMasse moléculaire :457.58EGFR/VEGFR2-IN-1
EGFR/VEGFR2-IN-1 (Compound 10e) serves as an inhibitor for VEGFR-2 and EGFR, with respective IC50 values of 0.26 and 0.14 μM. It inhibits microtubule protein polymerization with an IC50 of 40.9 μM and induces cell apoptosis (Apoptosis). EGFR/VEGFR2-IN-1 is applicable in research related to anti-leukemia and anti-lymphoma treatments.Couleur et forme :Odour SolidDisitamab vedotin
CAS :Disitamab vedotin (RC-48) is a HER2-targeting ADC with MMAE, effective in HER2-expressing gastric cancer.Degré de pureté :95.00% - 98%Couleur et forme :LiquidMasse moléculaire :149 kDaSIAIS178
CAS :SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Formule :C50H62ClN11O6S2Degré de pureté :98.07%Couleur et forme :SolidMasse moléculaire :1012.68Ref: TM-T12907
1mg152,00€5mg356,00€10mg485,00€25mg888,00€50mg1.431,00€100mg2.052,00€200mg2.673,00€1mL*10mM (DMSO)393,00€DD0-2363
DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.Formule :C36H36ClFN6O4Couleur et forme :SolidMasse moléculaire :671.16SNIPER(ABL)-024
CAS :SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,Formule :C52H61F3N8O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1031.15MR44397
MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.Formule :C23H26N4O2SCouleur et forme :SolidMasse moléculaire :422.54I-As-1
I-As-1 is a potent inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 2.35 nM. It exhibits antiproliferative activity against Ramos cells and OCI-LY10 cells, with IC50 values of 0.52 μM and 0.11 μM, respectively.Formule :C26H27AsN6O2S2Masse moléculaire :594.08529DBL-6-13
DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.Formule :C25H38N4O3Couleur et forme :SolidMasse moléculaire :442.59VEGFR-2-IN-56
VEGFR-2-IN-56 (compound 12e) exhibits the strongest inhibition activity against VEGFR-2, with an IC50 value of 45.9 nM.Couleur et forme :Odour SolidTYD-68
TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.Couleur et forme :Odour SolidGlaziovine
CAS :Glaziovine is an agent of anti-ulcerogenic natural alkaloid.Formule :C18H19NO3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :297.35FGFR-IN-19
Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.Formule :C36H42N12O6Couleur et forme :SolidMasse moléculaire :738.33503Depatuxizumab MMAF
Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.Couleur et forme :LiquidMasse moléculaire :148.24 kDaAnti-β Klotho Antibody (Fazpilodemab)
CAS :Fazpilodemab (BFKB8488A) is a humanized bispecific antibody that targets and activates the Klotho β and fibroblast growth factor receptor 1c receptor complex.Couleur et forme :LiquidMasse moléculaire :146 kDaZM 449829
CAS :ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.Formule :C13H10ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :182.222Gefitinib N-oxide hydrochloride
Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.Formule :C22H24ClFN4O41·5HClCouleur et forme :SolidMasse moléculaire :517.59SNIPER(ABL)-049
SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels,Formule :C52H66N10O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :959.14Itacitinib adipate
CAS :Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.Formule :C32H33F4N9O5Couleur et forme :SolidMasse moléculaire :699.66GW2974
CAS :GW2974, Oral EGFR/ErbB2 dual inhibitor, inhibits glioblastoma multiforme (GBM) cell invasion and tumor growth.Formule :C23H21N7Degré de pureté :99.43%Couleur et forme :SolidMasse moléculaire :395.46Lestaurtinib
CAS :Lestaurtinib (CEP 701) is a FLT3 inhibitor that inhibits the phosphorylation of RPTKs and can be used to study leukemia.Formule :C26H21N3O4Degré de pureté :99.17%Couleur et forme :Off-White SolidMasse moléculaire :439.46BI-3663
CAS :BI-3663 is a selective PTK2/FAK PROTAC with cereblon ligands, degrading PTK2 (IC50: 18 nM), and shows anti-cancer properties.Formule :C44H42F3N7O12Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :917.84DTP3
CAS :DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Formule :C26H35N7O5Couleur et forme :SolidMasse moléculaire :525.6PND-1186 hydrochloride
CAS :PND-1186 hydrochloride (VS-4718 hydrochloride) is a highly specific, reversible and potent inhibitor of FAK (IC50: 1.5 nM), which can selectively induceFormule :C25H27ClF3N5O3Couleur et forme :SolidMasse moléculaire :537.97
